Halozyme Therapeutics (NASDAQ:HALO) has tumbled 2.63% during the past week and has dropped 6.89% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.46%. Halozyme Therapeutics (NASDAQ:HALO) has underperformed the index by 7.73% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Halozyme Therapeutics (NASDAQ:HALO): The stock opened at $9.09 on Friday but the bulls could not build on the opening and the stock topped out at $9.09 for the day. The stock traded down to $8.47 during the day, due to lack of any buying support eventually closed down at $8.52 with a loss of -6.06% for the day. The stock had closed at $9.07 on the previous day. The total traded volume was 2,058,434 shares.
The company shares have dropped -61.38% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $25.25 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $9.43 and the 200 Day Moving Average price is recorded at $10.85.
On the companys insider trading activities, Stelzer Laurie, CFO of Halozyme Therapeutics Inc, executed a transaction worth $172,400 on August 20, 2015. A total of 10,000 shares were purchased at an average price of $17.24. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. In the latest statement by the brokerage house, JMP Securities maintains its outlook on Halozyme Therapeutics (NASDAQ:HALO). The current rating of the shares is Market Outperform, according to the research report released by the firm. The brokerage firm lowers the price target from $22 per share to $20 per share. The rating by the firm was issued on March 9, 2016. Currently the company Insiders own 16.6% of Halozyme Therapeutics shares according to the proxy statements. Institutional Investors own 78.53% of Halozyme Therapeutics shares.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.